Q-omics provides the consensus-scored NDFIP1 profile across patient tissues and cancer cell-line models. NDFIP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NDFIP1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, NDFIP1 RNA expression shows 19,752 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where NDFIP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDFIP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDFIP1 survival associations across molecular data types. NDFIP1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDFIP1 RNA expression–survival associations across cancer types. High NDFIP1 expression shows unfavorable associations in HNSC, SCLC, CESC and UVM, but favorable associations in KIRC and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NDFIP1 RNA expression.
This table summarizes NDFIP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NDFIP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDFIP1 shows lower tumor expression in THCA, LUSC, KIRC, UCEC and KIRP and higher tumor expression in LIHC. The THCA box plot shows higher NDFIP1 RNA expression in normal versus tumor tissue (log2 FC = −1.025, t-test p < 0.001).
This table shows molecular features associated with NDFIP1 in patient tissues and cancer cell lines. In patient samples, NDFIP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDFIP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
